Show simple item record

dc.contributor.authorKieler, Helle
dc.contributor.authorArtama, Miia
dc.contributor.authorEngeland, Anders
dc.contributor.authorEricsson, Örjan
dc.contributor.authorFuru, Kari
dc.contributor.authorGissler, Mika
dc.contributor.authorNielsen, Rikke Beck
dc.contributor.authorNørgaard, Mette
dc.contributor.authorStephansson, Olof
dc.contributor.authorValdimarsdottir, Unnur
dc.contributor.authorZoega, Helga
dc.contributor.authorHaglund, Bengt
dc.date.accessioned2022-05-11T08:44:14Z
dc.date.available2022-05-11T08:44:14Z
dc.date.issued2012-01-12
dc.description.abstractObjective To assess whether maternal use of selective serotonin reuptake inhibitors (SSRIs) increases the risk of persistent pulmonary hypertension in the newborn, and whether such an effect might differ between specific SSRIs.<p> <p>Design Population based cohort study using data from the national health registers.<p> <p>Setting Denmark, Finland, Iceland, Norway, and Sweden, 1996-2007.<p> <p>Participants More than 1.6 million infants born after gestational week 33.<p> <p>Main outcome measures Risks of persistent pulmonary hypertension of the newborn associated with early and late exposure to SSRIs during pregnancy and adjusted for important maternal and pregnancy characteristics. Comparisons were made between infants exposed and not exposed to SSRIs.<p> <p>Results Around 30 000 women had used SSRIs during pregnancy and 11 014 had been dispensed an SSRI later than gestational week 20. Exposure to SSRIs in late pregnancy was associated with an increased risk of persistent pulmonary hypertension in the newborn: 33 of 11 014 exposed infants (absolute risk 3 per 1000 liveborn infants compared with the background incidence of 1.2 per 1000); adjusted odds ratio 2.1 (95% confidence interval 1.5 to 3.0). The increased risks of persistent pulmonary hypertension in the newborn for each of the specific SSRIs (sertraline, citalopram, paroxetine, and fluoxetine) were of similar magnitude. Filling a prescription with SSRIs before gestational week 8 yielded slightly increased risks: adjusted odds ratio 1.4 (95% confidence interval 1.0 to 2.0).<p> <p>Conclusions The risk of persistent pulmonary hypertension of the newborn is low, but use of SSRIs in late pregnancy increases that risk more than twofold. The increased risk seems to be a class effect.en_US
dc.identifier.citationKieler H, Artama, Engeland A, Ericsson, Furu K, Gissler M, Nielsen, Nørgaard M, Stephansson, Valdimarsdottir U, Zoega, Haglund B. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. British Medical Journal. 2012;344en_US
dc.identifier.cristinIDFRIDAID 922791
dc.identifier.doi10.1136/bmj.d8012
dc.identifier.issn0959-8146
dc.identifier.urihttps://hdl.handle.net/10037/25071
dc.language.isoengen_US
dc.publisherBMJen_US
dc.relation.journalBMJ. British Medical Journal
dc.relation.urihttp://www.bmj.com/highwire/filestream/557867/field_highwire_article_pdf/0.pdf
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2012 The Author(s)en_US
dc.subjectVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756en_US
dc.subjectVDP::Midical sciences: 700::Clinical medical sciences: 750::Gynaecology and obstetrics: 756en_US
dc.subjectKardiovaskulær medisin / Cardiovascular medicineen_US
dc.subjectLungesykdommer / Lung Diseasesen_US
dc.subjectMor-barn helse / Mother-child healthen_US
dc.subjectSpedbarn / Infanten_US
dc.titleSelective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countriesen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record